Boston Scientific (BSX) reported $5.29 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 15.9%. EPS of $0.80 for the same period compares to $0.70 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $5.27 billion, representing a surprise of +0.39%. The company delivered an EPS surprise of +2.96%, with the consensus EPS estimate being $0.78.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Rest of the World: $1.9 billion versus $1.88 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +13.8% change.
- Geographic Revenue- U.S.: $3.39 billion versus $3.39 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +17% change.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- International: $228 million versus the two-analyst average estimate of $230.37 million. The reported number represents a year-over-year change of +4.6%.
- Net Sales- Cardiovascular- International: $1.33 billion versus $1.34 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.3% change.
- Net Sales- Cardiovascular- Worldwide: $3.48 billion versus $3.46 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +18.2% change.
- Net Sales- MedSurg- Worldwide: $1.81 billion compared to the $1.8 billion average estimate based on six analysts. The reported number represents a change of +11.7% year over year.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $332 million versus the five-analyst average estimate of $320.38 million. The reported number represents a year-over-year change of +11%.
- Net Sales- MedSurg- Urology- Worldwide: $717 million versus the five-analyst average estimate of $725.74 million. The reported number represents a year-over-year change of +13.8%.
- Net Sales- MedSurg- Endoscopy- Worldwide: $760 million versus the five-analyst average estimate of $756.05 million. The reported number represents a year-over-year change of +10.1%.
- Net Sales- Cardiovascular- Watchman- Worldwide: $535 million compared to the $538.6 million average estimate based on four analysts. The reported number represents a change of +29.5% year over year.
- Net Sales- Cardiovascular- Electrophysiology- Worldwide: $890 million versus $923.99 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +37.1% change.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $587 million compared to the $585.96 million average estimate based on four analysts. The reported number represents a change of +3.7% year over year.
View all Key Company Metrics for Boston Scientific here>>>
Shares of Boston Scientific have returned -6.3% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
